Canine Lymph Node Metastasis TCC Cell Line (KU-CTCC-001-LM3)

Description

KU-CTCC-001-LM3, established from a metastatic lymph node of the same patient as KU-CTCC-001 Cat. T8165 , harbors the BRAF V595E mutation and displays activated MAPK signaling. This cell line presents a unique model to study metastatic processes, offering insights into the molecular and cellular mechanisms underlying TCC spread. Its growth characteristics and sensitivity to BRAF inhibitors, including a notable response to sorafenib, make it a critical tool for advancing understanding of metastasis, evaluating therapeutic strategies for metastatic disease, and contributing to the development of personalized medicine approaches in canine and human oncology. Note: KU-CTCC-001-LM3, derived from a metastatic site, enables focused research on the metastatic behavior and potential therapeutic targets specific to TCC metastasis, compared to KU-CTCC-001 Cat.T8165 and KU-CTCC-002 Cat.T8166 , which are derived from primary tumors. Its slightly slower proliferation rate in vitro versus KU-CTCC-001 Cat. T8165 might reflect differences in growth dynamics between primary and metastatic cancer cells. Complete list of cell lines from this panel: Cat. T8165 - Canine Transitional Cell Carcinoma Cell Line KU-CTCC-001 Cat. T8166 - Canine Transitional Cell Carcinoma Cell Line KU-CTCC-002 Cat. T8167 - Canine Lymph Node Metastasis TCC Cell Line KU-CTCC-001-LM3